Despite the development of new biological and synthetic targeted therapies, methotrexate
remains one of the most commonly used immunomodulatory drugs in rheumatology …

In patients with autoimmune rheumatic disease, methotrexate therapy has been associated
with poor immune response to vaccines, including those intended to provide protection …

Objective To study the effect of methotrexate (MTX) and its discontinuation on the humoral
immune response after COVID-19 vaccination in patients with autoimmune rheumatic …

Background Methotrexate is the first-line treatment for immune-mediated inflammatory
diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of …

To assess the humoral response to vaccination against SARS-CoV-2 in patients with
rheumatoid arthritis treated with methotrexate (MTX). In total, 142 fully vaccinated individuals …

Immunosuppressants, such as methotrexate (MTX), can suppress the COVID-19 vaccine
response in patients with autoimmune diseases. Thus, this study aims to evaluate the effects …

COVID-19 vaccines exhibit high levels of immunogenicity in the overall population. Data on
the effects of immunomodulators on the consequences of COVID-19 in patients with Immune …

The COVID-19 pandemic has brought the debate about methotrexate (MTX) discontinuation
and vaccine response back to the forefront. This issue cannot leave the rheumatology …

Abstract Purpose of Review To review the impact of disease-modifying antirheumatic drugs
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …

B and T cell responses were evaluated in patients with rheumatoid arthritis (RA) or psoriatic
arthritis (PsA) after 1 or 2 weeks of methotrexate (MTX) withdrawal following each COVID-19 …